Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities (Tables)

v3.5.0.2
Accrued Expenses and Other Long-Term Liabilities (Tables)
9 Months Ended
Sep. 30, 2016
Schedule of Accounts Payable and Accrued Liabilities
Accrued expenses and other long-term liabilities, excluding National, consisted of the following:
 
 
 
September 30,
 
December 31,
 
($ in thousands)
 
2016
 
2015
 
Accrued expenses:
 
 
 
 
 
 
 
Professional fees
 
$
1,389
 
$
382
 
Salaries, bonuses and related benefits
 
 
1,777
 
 
2,492
 
Ovamed manufacturing rights - short term component
 
 
750
 
 
1,500
 
Research and development
 
 
788
 
 
810
 
Dr. Falk Pharma milestone
 
 
2,802
 
 
2,717
 
Accrued royalty and coupons
 
 
301
 
 
-
 
Lease impairment
 
 
95
 
 
146
 
Other
 
 
703
 
 
523
 
Total accrued expenses
 
$
8,605
 
$
8,570
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
Deferred rent and long-term lease abandonment charge
 
 
4,583
 
 
584
 
Total other long-term liabilities
 
$
4,583
 
$
584
 
National Holdings Corporation [Member]  
Schedule of Accounts Payable and Accrued Liabilities
National's preliminary allocation of fair value of accounts payable and other accrued expenses as of September 9, 2016, consisted of the following:
 
 
 
September 9,
 
($ in thousands)
 
2016
 
Legal
 
$
961
 
Audit
 
 
196
 
Telecommunications
 
 
181
 
Data Services
 
 
229
 
Regulatory
 
 
365
 
Settlements
 
 
701
 
Deferred rent
 
 
39
 
Contingent consideration payable
 
 
423
 
Other
 
 
2,984
 
Total
 
$
6,079